Jade Biosciences, Inc.
JBIO Nasdaq
SEC CIK 1798749
Follow Jade Biosciences
Weekly email: filings, results
Net income
−$35.1M
−39.2% vs same quarter last year
EPS, diluted
−$0.42
+12.5% vs same quarter last year
Operating cash flow
−$28.9M
−30.7% vs same quarter last year
Operating income
−$39.6M
−44.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$127.4M |
| FY24 | −$69.6M |
| FY23 | −$75.5M |
| FY22 | −$51.5M |
| FY21 | −$23M |
| FY20 | −$9.6M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$94.9M |
| FY24 | - |
| FY23 | −$56.9M |
| FY22 | −$39.3M |
| FY21 | −$27.6M |
| FY20 | - |
| FY19 | - |